

SAN DIEGO, CA, October 05, 2013 **/24-7PressRelease/** -- Xavier Jacq, a Co-founder of MISSION Therapeutics, where he heads the Biology and Screening Activities team, will give a presentation at the 4th Ubiquitin Research and Drug Discovery Conference, to be held in San Diego, CA on February 20-21, 2014 by GTC.

He is an inventor of multiple patents related to inhibitors of deubiquitylating enzymes and assays. Previously, Xavier joined KuDOS Pharmaceuticals in Cambridge, UK as a team leader and project leader in the field of DNA-damage response and was involved in carrying successful pre-clinical projects in collaboration with colleagues at AstraZeneca.

The 4th Ubiquitin Research and Drug Discovery Conference is the premier conference that hosts an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities. The conference will focus on drug discovery aspects within the ubiquitin pathway. Topics to be discussed include deubiquitinating enzymes as drug targets, novel drug targets in the ubiquitin system, ubiquitin-like modifications, ubiquitin pathways in neurobiology, ubiquitin proteasome system and oncology, and proteasome structure and function.

This conference is part of the Future Biotech Summit 2014, which consists of the following co-located conferences:

1) 4th Ubiquitin Research and Drug Discovery 2) 2nd Orphan Drug Research 3) Cell and Gene Therapy

For more information, please visit <http://www.gtcbio.com/conference/ubiquitin/agenda>

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.